| 000 | 01806 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250513120843.0 | ||
| 264 | 0 | _c19970829 | |
| 008 | 199708s 0 0 eng d | ||
| 022 | _a0920-9964 | ||
| 024 | 7 |
_a10.1016/s0920-9964(96)00115-6 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMolina Rodríguez, V | |
| 245 | 0 | 0 |
_aCerebral perfusion correlates of negative symptomatology and parkinsonism in a sample of treatment-refractory schizophrenics: an exploratory 99mTc-HMPAO SPET study. _h[electronic resource] |
| 260 |
_bSchizophrenia research _cMay 1997 |
||
| 300 |
_a11-20 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAntipsychotic Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aBrain _xblood supply |
| 650 | 0 | 4 | _aBrain Mapping |
| 650 | 0 | 4 | _aChronic Disease |
| 650 | 0 | 4 |
_aDepression _xdiagnostic imaging |
| 650 | 0 | 4 |
_aDominance, Cerebral _xdrug effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aOrganotechnetium Compounds |
| 650 | 0 | 4 | _aOximes |
| 650 | 0 | 4 |
_aParkinson Disease, Secondary _xchemically induced |
| 650 | 0 | 4 | _aPsychiatric Status Rating Scales |
| 650 | 0 | 4 |
_aRegional Blood Flow _xdrug effects |
| 650 | 0 | 4 |
_aSchizophrenia, Paranoid _xdiagnostic imaging |
| 650 | 0 | 4 | _aTechnetium Tc 99m Exametazime |
| 650 | 0 | 4 | _aTomography, Emission-Computed, Single-Photon |
| 650 | 0 | 4 | _aTreatment Failure |
| 700 | 1 | _aMontz Andrée, R | |
| 700 | 1 | _aPérez Castejón, M J | |
| 700 | 1 | _aGutiérrez Labrador, R | |
| 700 | 1 | _aFerre Navarrete, F | |
| 700 | 1 | _aCarreas Delgado, J L | |
| 700 | 1 | _aRubia Vila, F J | |
| 773 | 0 |
_tSchizophrenia research _gvol. 25 _gno. 1 _gp. 11-20 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/s0920-9964(96)00115-6 _zAvailable from publisher's website |
| 999 |
_c9157996 _d9157996 |
||